Entera Bio (ENTX) Short-term Investments (2017 - 2025)
Entera Bio (ENTX) posted quarterly Short-term Investments of $7.8 million for Q4 2025, up 800.93% on a QoQ basis from $863000.0 in Q2 2021.
Entera Bio (ENTX) Short-term Investments (2017 - 2025) Analysis & Trends
Entera Bio (ENTX) has reported Short-term Investments for 6 consecutive years, with $7.8 million the latest figure, recorded in Q4 2025.
- Quarterly Short-term Investments changed N/A year-over-year to $7.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.8 million (changed N/A YoY) and the FY2025 annual result came in at $7.8 million, changed N/A from the prior year.
- Short-term Investments rose to $7.8 million in Q4 2025 per ENTX's latest filing, from $863000.0 in the prior quarter.
- Over the last five years, Short-term Investments for ENTX reached as high as $7.8 million in Q4 2025 and fell as low as $863000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.78 Mn |
| Jun 30, 2021 | 863,000.00 |
| Dec 31, 2020 | 261,000.00 |
| Jun 30, 2020 | 677,000.00 |
| Dec 31, 2019 | 173,000.00 |
| Dec 31, 2018 | 220,000.00 |
| Dec 31, 2017 | 671,000.00 |